STOCK TITAN

Aerovate Therapeutics Inc - AVTE STOCK NEWS

Welcome to our dedicated news page for Aerovate Therapeutics (Ticker: AVTE), a resource for investors and traders seeking the latest updates and insights on Aerovate Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Aerovate Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Aerovate Therapeutics's position in the market.

Rhea-AI Summary
Aerovate Therapeutics, Inc. (Nasdaq: AVTE) announces completion of Phase 2b enrollment for the IMPAHCT trial evaluating AV-101, a novel dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension (PAH). More than 120 sites are actively recruiting patients for the Phase 3 portion, with topline data from the Phase 2b expected in June 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.07%
Tags
clinical trial
-
Rhea-AI Summary
Aerovate Therapeutics, Inc. (Nasdaq: AVTE) Announces Financial Results and IMPAHCT Global Phase 2b/Phase 3 Clinical Trial Progress
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.45%
Tags
earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.35%
Tags
earnings
Rhea-AI Summary
Aerovate Therapeutics has appointed Habib Dable as a member of its Board of Directors. Dable brings nearly three decades of experience in the biotech industry and has a successful track record in leading big pharma and emerging biotech companies. He will provide valuable expertise as Aerovate continues to develop AV-101, a novel dry powder inhaled formulation of the drug imatinib, for the treatment of pulmonary arterial hypertension (PAH). Dable's appointment strengthens the diverse expertise of the Board and supports the company's ongoing growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.45%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.32%
Tags
conferences
-
Rhea-AI Summary
Aerovate Therapeutics, Inc. (Nasdaq: AVTE) announced that the topline Phase 2b data for the IMPAHCT global Phase 2b/Phase 3 clinical trial of AV-101 for pulmonary arterial hypertension (PAH) is now expected in the second quarter of 2024. Over 100 sites have been activated in 20 countries, and enrollment is increasing. The company is sufficiently funded into the second half of 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.45%
Tags
earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.05%
Tags
earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.23%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.27%
Tags
management
Aerovate Therapeutics Inc

Nasdaq:AVTE

AVTE Rankings

AVTE Stock Data

659.35M
9.67M
0.03%
104.22%
4.06%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States
Waltham

About AVTE

aerovate is a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease. aerovate's initial focus is on advancing av-101, its dry powder inhaled formulation of the drug imatinib for the treatment of pulmonary arterial hypertension, or pah.